NEW YORK (GenomeWeb) – Prescient Medicine announced today that it has acquired Kentucky-based pharmacogenomics testing reference lab PGxL Laboratories.
Prescient offers toxicology, pharmacogenomic, and other testing, including a recently launched service called LifeKit Predict that predicts patients' risk for opioid addiction based on their genetic profiles. According to Prescient, the acquisition will expand its lab capabilities and enhance its relationships with local, regional, and national health insurers. The firm added that it expects to begin processing its tests at the PGxL facility by the end of the year.
Specific terms of the deal were not disclosed.
"The purchase of PGxL is an opportunity to better service the growing list of clinics, doctors, and patients who see the value in important clinical tools like LifeKit Predict," Prescient Founder and CEO Keri Donaldson said in a statement.